Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction therapy. Eligible patients received four induction cycles with FEC 100 The outcome of patients diagnosed with metastatic breast cancer remains poor. Although advanced cancers respond to conventional chemotherapy and hormonal therapy, most patients will ultimately relapse and die of their disease. 1 The large number of clinical studies conducted over the past 20 years, and the arrival of new cytotoxic drugs or hormonal treatments had only a small impact on overall survival (OS) rates, and median survival remains less than 36 months in most series. 2 The optimal treatment for metastatic breast cancer remains undefined, although it is now clear that it could possibly vary according to the different molecular subtypes. 3 In unselected series of patients, conventional combination chemotherapy regimens with anthracyclines and/or taxanes have achieved good results with overall objective response rates of 40% (range 15-80%). 4, 5 However, despite complete response (CR) rates averaging 10%, a duration of response around 10 months, and a 5-year disease-free survival (DFS) of 3%, the effect on survival is limited as compared to previous combination CT or singleagent treatment. [6] [7] [8] The lack of effective treatments for this patient group was the driving force behind the development of more aggressive chemotherapy regimens 10 years ago.
The importance of dose intensity in achieving maximum tumor response in metastatic breast cancer has been well established. 9 Using PBSC support after high-dose chemotherapy (HDC) allows the dose of chemotherapy to be increased up to fivefold. Results from early small nonrandomized clinical trials were encouraging, with reports of improved survival in metastatic breast cancer patients following treatment with HDC and autologous blood stem cell transplantation. [10] [11] [12] [13] However, several of these earlier results have been criticized for biases in patient recruitment and study design 14 and many questions remain unanswered regarding the treatment of metastatic breast cancer with HDC. 15 Although the high response rates obtained have shown non-inferiority of HDC compared to conventional regimens, improved survival has not been demonstrated.
Furthermore, phase III trials have failed to show any increase in long-term survival ratio. 17, 18 With many questions on the possible limitations of HDC unanswered, it is widely accepted that this therapy warrants further investigation through large, prospective, randomized phase III trials.
We report the long-term results of a phase III trial investigating the efficacy of HDC (cyclophosphamide and thiotepa) with PBSC as first-line treatment for metastatic breast cancer in patients who responded to induction therapy with four cycles of 5-fluorouracil þ epirubicin þ cyclophosphamide (FEC). Dose selection for the intensification protocol was based on the works of Kennedy et al.
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Patients and methods
Patient selection
To be eligible, patients had to have histologically proven metastatic breast cancer (and/or local or regional relapse beyond curative treatment by surgery or radiotherapy), with at least one measurable lesion to allow objective evaluation of response. All patients were required to display signs of disease progression within 1 month of inclusion into the study, whether or not they were receiving hormone therapy. Additional patient eligibility criteria included age o60 years, a World Health Organization (WHO) performance status of p2, and life expectancy of at least 3 months. Exclusion criteria were: bone, ascites, pleural effusion, or pulmonary or cutaneous lymphangitis as the only metastatic site; clinically detectable meningeal or cerebral metastases; prior palliative chemotherapy (adjuvant chemotherapy stopped for at least 1 year before inclusion and/or hormonal therapy were not reasons for exclusion); prior adjuvant chemotherapy with anthracyclines at a cumulative dose of epirubicin (4450 mg/m Further exclusion criteria were: cardiac disease, either clinically evident (congestive heart disease or myocardial infarction within the previous 6 months) or visible on an electrocardiogram or as a pathological left ventricular ejection fraction at rest; radiotherapy to more than onethird of hematopoietic regions within 6 weeks of inclusion into the study; inadequate bone marrow function (absolute neutrophil count o2 Â 10 9 /l or platelets o100 Â 10 9 /l); serum bilirubin 435 mmol/l and/or serum creatinine 4130 mmol/l; presence of infection; pregnancy; concurrent malignancy at another site (with exception of in situ carcinoma of the uterine cervix or squamous cell carcinoma of the skin); psychiatric or any other reason that would prevent regular follow-up. Investigations before treatment included general medical history, history of cancer, physical examination, vital signs, electrocardiogram, pathological left ventricular ejection fraction, evaluation of breast cancer and extent of disease (chest X-ray, ultrasound or CT scan of liver, bone and bone marrow), and laboratory data (hematology, clinical chemistry, carcinoembryonic antigen and CA 15-3). All patients gave signed informed consent.
Study design
This was an open, randomized, multicenter phase III trial of first-line chemotherapy in female patients with metastatic breast cancer recruited at 22 centers in France, and one in Italy. The study design is outlined in Figure 1 . All eligible patients entered the induction phase, and received , by i.v. infusion once every 21 days. Patients with a complete or partial response (PR) 450% after four cycles were randomized (1:1) to arm A (no further treatment, observation only) or arm B (intensification therapy with HDC and autologous PBSC transplantation). Patients in both arms were observed until disease progression. Those patients with progressive or stable disease after four cycles of FEC100 were excluded from the study, but followed for survival; subsequent treatment for this group was left to the discretion of each individual investigator.
Cycles of FEC were delayed by 8 days in the case of myelosuppression (neutrophils o1.8 Â 10 9 /l or platelets o100 Â 10 9 /l) to allow for recovery of cell count. Patients whose cell counts had not recovered by day 28 were discontinued from the study. Patients who experienced febrile neutropenia (fever 38.3 1C and neutrophils o0.5 Â 10 9 /l) were treated with antibiotics, and continued in the study with no change to the dose of study drugs if the febrile neutropenia had resolved. For all subsequent cycles, patients who experienced febrile neutropenia or myelosuppression at day 21 were given G-CSF (5 mg/kg/day) from days 5 to 14. In the case of unresolved grade 3 or 4 mucositis at day 21, the dose of study drugs was reduced by 25% for remaining cycles.
On day 1 of each FEC cycle a physical examination and electrocardiogram were performed, vital signs measured and laboratory data collected. Laboratory data were also collected and pathological left ventricular ejection fraction measured after cycles 2 and 4 (and cycle 3 if indicated).
Autologous PBSC transplantation
Once a response (CR or PR 450%) was obtained and randomization had taken place, patients in arm B underwent PBSC harvesting prior to receiving intensification chemotherapy. This treatment was performed after the third or fourth cycle of FEC100. Mobilization of PBSC was performed using a G-CSF, filgrastim (Neupogen s , Amgen, Neuilly, France), at a dose of 5 mg/kg/day from day 5 until the day before the last apheresis. PBSCs were harvested by apheresis once there was recovery from the nadir (usually around days 10-12), according to the standard procedure of the center. From one to three aphereses were necessary to collect 4 Â 10 6 /kg body weight CD34 þ cells, which were cryopreserved at À190 1C until reinfusion after HDC. If the target of 4 Â 10 6 /kg could not be achieved, a minimum of 1.2 Â 10 6 /kg was mandatory and bone marrow harvest was performed if necessary. CD34 þ cells were not further characterized. Evaluation of response to induction treatment An evaluation of the extent of disease in the breast, bone, liver, lungs and lesions was made after cycles 2 and 4 (and cycle 3 if indicated) and again before randomization. All patients who received at least two cycles of FEC100 were evaluable for response. Response criteria depended on whether the patient had measurable or non-measurable disease and were defined using standard guidelines.
Intensification with PBSC reinfusion and G-CSF support
Post-therapy follow-up
An evaluation identical to that performed at baseline was carried out 12 weeks after completing cycle 4 of FEC, or 6-9 weeks after intensification. Subsequent evaluations were performed every 3 months for the first 3 years or until relapse, then every 6 months in the case of continuing remission. At the time of disease progression, subsequent treatment was at the discretion of the treating clinician; progress of the disease and duration of survival were recorded.
Statistical methods
Duration of survival was measured as the period from the first day of treatment with FEC100 to death; DFS was measured as the period from the first day of treatment to progression of existing lesions or appearance of new lesions. OS and DFS curves were estimated using the Kaplan-Meier method. The primary end point was the 3-year OS rate. The number of patients needed for the study was calculated using the Freedman method. 20 In order to have 90% power to detect an improvement in survival of 20% at 3 years (passage from 25% in the conventional chemotherapy group to 45% after intensification), it was necessary to randomize 180 patients. The secondary end points were the DFS and the tumor response rate after intensification.
Results
A total of 308 patients entered the study between January 1995 and June 2001. Of these, 179 had a validated CR or PR 450% after induction therapy and were randomized to receive intensification treatment with HDC (N ¼ 88) or no further treatment (N ¼ 91) ; the remaining patients (N ¼ 129) were not randomized (Figure 1 ).
Patient characteristics
Patient characteristics are given in Table 1 . A total of 141 out of the 308 patients enrolled (46.2%) received prior adjuvant chemotherapy (data unavailable for three patients). The median delay between the end of adjuvant chemotherapy and the first FEC cycle was 32.5 months (range 8.3-157.6); three patients had less than a 12-month delay since the end of adjuvant chemotherapy.
With respect to randomized patients, the number of estrogen receptor/progesterone receptor-positive patients was slightly higher in the intensification group (65.8 and 60%) compared to the observation group (53.2 and 42.3%). During the trial, it was recommended to give no hormonal therapy until relapse. Estrogen receptor-positive patients received further treatment in both arms. The intensification group also had a slightly higher number of patients with liver and distant lymph node metastases (56.8 and 40.9 versus 49.5 and 34.1%, respectively), but fewer patients with lung metastases (29.6 versus 34.1%, respectively), compared to the observation group. Unfortunately, at the time of data collection for this multicenter study, the Her-2/Neu status of the patients was not available.
Toxicity and response to induction therapy A total of 308 patients received at least one cycle of FEC100. Thirty-four discontinued the study before the fourth cycle, mostly for progression (23 patients) or toxicity (7 patients). Finally, 274 patients completed the four cycles of induction therapy as planned by the protocol. Toxicity was manageable. Grade 3 or 4 neutropenia occurred in about 50% of patients in the first FEC cycle; for these patients, subsequent cycles were given with G-CSF from days 5 to 14, inclusive. There was one toxic death.
Response rates were assessed despite the difficulty in determining CR rate in bone lesions. After the four cycles of induction, 15 patients were in CR (4.8%) and 170 patients were in PR (55%). The overall response rate was 60%. Among the responding patients, 91 were randomized to the observation group, 88 to the intensification group and 7 refused to be randomized. The response after four cycles of FEC100 for each group of patients is summarized in Table 2 .
Intensification therapy A total of 84 out of the 88 randomized patients in the intensification arm underwent stem cell harvesting. The remaining four did not for the following reasons: neutropenia (one patient), patient refusal (one patient) and progressive disease (two patients). Eventually, 79 patients received one cycle of CHUT with stem cell reinfusion. Five patients did not receive the graft for the following reasons: apheresis failure (two patients), progressive disease (two patients) and toxicity (one patient). Three patients who were randomized to 'observation only' also received one cycle of CHUT: one on the patient's request and two after relapse. The median time between the fourth FEC cycle and reinfusion of stem cells was 40 days (range 26-84). The median total CD34 þ cells harvested per patient was 4.9 Â 10 6 /kg (range 1.4-23.6) and the median number reinfused was 4.7 Â 10 6 /kg (range 1.4-19.6). Of the 79 grafts performed, 76 were with PBSC, two were bone marrow grafts and one was bone marrow plus PBSC. The median durations of grade 4 neutropenia and grade 4 thrombocytopenia were 10 and 7 days, respectively; the median durations of grade 3 neutropenia and grade 3 thrombocytopenia were 11 and 12 days, respectively; 86.1% of patients required one or more transfusions of RBCs and all 79 patients required one or more transfusions of platelets. Grade 3 or 4 non-hematological toxicities were reported in the following numbers of patients: infection (24/79; 30.4%), mucositis (43/79; 54.4%), nausea and vomiting (39/79; 49.4%) and neurological toxicity (2/79; 2.6%). Grade 3 or 4 cardiac and renal toxicities were High-dose chemotherapy in metastatic breast cancer P Biron et al not observed. There was one toxic death post-CHUT from veno-occlusive disease.
Response and survival Median follow-up was 48 months. Both overall and CR rates 3 months after randomization were significantly higher (P ¼ 0.01) in the intensification arm than in the observation arm: 82.7% (25.3% CR) versus 59.2% (14.1% CR), respectively (Table 3 ). In contrast, at the time of analysis, the number of relapses was higher in the observation arm than in the intensification arm: 87 (95.6%) versus 73 (82%), respectively. The 1-, 2-and 3-year DFS rates were also in favor of the intensification arm: 46.2 versus 16.7%, 25.2 versus 4.2% and 8.8 versus 2.1% (P ¼ 0.0001), respectively. Median DFS was 11 months in the intensification arm versus 6.6 months in the observation arm (Figure 2 ). However, there was no difference in OS rates between the two arms. At 3 years, the rates were 33.6% in the intensification arm and 24.3% in the observation arm (P ¼ 0.8). Median OS was 22.9 versus 23.9 months, respectively ( Figure 3 ).
Discussion
The Pegase 03 study reported here is one of seven trials set up in 1994 as a French national program to address the issue of HDC in breast cancer. 21 Pegase 03 evaluated the effect of HDC with autologous PBSC support on the 3-year survival rate of patients with metastatic breast cancer who had responded to four cycles of induction therapy with FEC. Responding patients in the other arm received no further treatment, but were observed until disease progression. With a median follow-up of 48 months, there were statistically significant differences in DFS at 1 year in favor of HDC compared to observation only (median DFS: 11 versus 6.6 months, P ¼ 0.0001). However, this did not translate into a significant benefit in terms of OS, with a 3-year OS rate of 33.6 versus 24.3% (P ¼ 0.8). Such an observation is frequent in the field of HDC for solid tumors. It could be due to contamination of the graft by tumor cells, to the selection of more resistant cells due to dose intensity of the chemotherapy or to poor marrow tolerance to further chemotherapy.
With regard to toxicity, we reported one toxic death among the 84 patients who underwent stem cell harvesting (1/84, 1.2%). This compares favorably with results from similar trials, which have reported rates between 0 and 2.5%. 16 Hematological toxicity was manageable in our study following one cycle of CHUT, although 86.1% of the patients required one or more blood transfusions and all patients had at least one transfusion of platelets. There were no episodes of grade 3 or 4 cardiac or renal toxicity. Toxicity is an acknowledged risk with HDC; merged data from five randomized trials have shown that there were more treatment-related deaths and a greater incidence of adverse events in the HDC arms than the control arms. 15 However, although there is evidence that HDC per se is associated with greater mortality and morbidity than are conventional regimens, it seems that the toxicities differ significantly between the various regimens. 22 With regard to DFS and OS, our results are similar to those reported in the other six randomized trials of HDC with PBSC support used for the treatment of metastatic breast cancer. 18, [23] [24] [25] [26] [27] These six trials, plus interim results from Pegase 03, have been discussed in reviews. 6, 15, 28 High-dose chemotherapy in metastatic breast cancer P Biron et al
The number of patients studied in these randomized trials is still small and premature conclusions should not be drawn. 29 As data mature, or if additional trials enrolling larger numbers of patients are conducted, small but clinically important differences might emerge. 29, 30 Indeed, a recent review has highlighted the fact that the clinical benefit already observed with HDC should not be underrated, 29 and it cannot be excluded that a subgroup of patients might emerge, which would benefit from HDC. 23 It is important that the heterogeneity of breast cancer patients should be addressed in future evaluations of HDC, and that patients are enrolled according to multiple and well-defined risk factors. 31 Nevertheless, some authors argue that given the short natural history of metastatic breast cancer, the conclusions of available trials are unlikely to be altered by longer observation periods. 6 This absence of convincing evidence of a survival benefit of HDC over conventional therapies has led clinicians to question its benefits in breast cancer, and to discuss whether and to whom it should be administered. 15, 31 Explanations for the lack of benefit in long-term OS include the possibility that minimal residual disease remains after HDC and that the eventual relapse in responding patients is due to the presence, in the mobilized PBSC, of contaminating clonogenic tumor cells. 30, 32 Improved processing and purging techniques may minimize or eliminate relapses and have a positive effect on outcome. However, another and more likely explanation might be that HDC fails to kill the entire cancer cell population and that the residual cell population consists of more aggressive cells, which have become resistant to conventional chemotherapy. Better results may be obtained through intensifying the therapy. We only used one cycle of HDC in our study. It is possible that sequential cycles of HDC would improve OS rates. On the basis of observation that CR after HDC is the most significant prognostic factor for prolonged DFS, 33, 34 one phase II study has investigated the possibility of increasing the number of patients remaining disease-free by increasing CR rates by repetitive HDC dosing. 35 This study has reported an overall response rate of 87%; 30% of patients were progression-free at 31 months with a median follow-up of 31 months, and OS was 61%. The authors concluded that sequential HDC is feasible and induces a high response rate. Results from another study investigating the feasibility of four cycles of ablative HDC (cyclophosphamide and thiotepa) with PBSC support are also encouraging but show that high toxicity may preclude the development of such treatments. 36 Another approach to potentially increasing the efficacy of HDC is to give it very soon after the start of treatment, rather than later as a consolidation therapy. We attempted to evaluate such an approach in a phase II randomized trial (in three centers) comparing the use of very high-dose intensification before or after two sequential cycles of HDC, but a high toxicity rate in the second option necessitated premature termination of randomization.
Finally, in the age of personalized medicine, progress in genomic and proteomic analyses may hold the key to efficient selection of patients for high-dose therapy in association with targeted therapy. 37 In conclusion, our results show that, when used as late consolidation after first-line chemotherapy in metastatic breast cancer patients, HDC (with CHUT) and stem cell support significantly improve DFS and response rates, but have no effect on long-term survival. This corroborates findings from earlier randomized trials and supports a lack of efficacy of such an approach when applied to the general population of metastatic breast cancer patients. Further studies are needed to improve these results.
